维普期刊资源整合服务平台（V6.5）

178篇 您的检索式：作者名="Demetri G"

选中清除导出查看参考文献查看引证文献引用追踪共9页首页上一页第1页下一页末页 /9 跳转

	题名	作者	年代	出处	被引量
1	Biliary wound healing, ductular reactions, and IL-6/gp130 signaling in the development of liver disease显示文摘在胆汁的树上的 Basic 和翻译创伤愈合研究在皮和胃肠道上在类似的研究后面显著地落后。这是至少对为学习的胆道的容易的存取的缺乏部分可归因。但是临床的关联,对胆汁的上皮的房间(BEC ) 的更多的兴趣 BEC 文化的病理生理学,和普遍可获得性是颠倒这个趋势的因素。在额外肝的胆汁的树上,徒劳的创伤愈合,结疤,苛评开发紧迫发出。在损害的最小的 intra 肝的胆汁管任何一个, BEC 增长或繁的回答能贡献肝疾病。在大、小的胆汁管的慢性炎和坚持的创伤愈合反应经常导致肝癌症。当他们适用于胆道,依赖于表明小径的 IL-6/gp130/STAT3 的细胞的过程的重要性,未答复的问题,和未来方向,愈合的创伤的一般概念被讨论。	A J Demetris John G Lunz Ⅲ Susan Specht Isao Nozaki	2006	World Journal of Gastroenterology2006，12，22：	15
2	Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial显示文摘	Ronald P DeMatteo Karla V Ballman Cristina R Antonescu Robert G Maki Peter WT Pisters George D Demetri Martin E Blackstein Charles D Blanke Margaret von Mehren Murray F Brennan Shreyaskumar Patel Martin D McCarter Jonathan A Polikoff Benjamin R Tan Kouros	2009	The Lancet2009，，9669：	2
3	Markers of angiogenesis and clinical {eatures in patients with sarcoma显示文摘	DuBois S Demetri G	2007	Cancer2007，109，5：	1
4	Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib:a randomised controlled trial显示文摘	DEMETRI G D van OOSTEROM A T GARRETT C R	2006	Lancet2006，368，9544：	1
5	Medical management of unresectable,recurrent low-grade retroperitoneal liposarcoma:Integration of cytotoxic and non-cytotoxic therapies into multimodality care显示文摘	Goss G Demetri G	2000	Surg Oncol2000，9，：	1
6	Salt stress impact on the molecular structure and function of the photo-synthetic apparatus -the protective role of polyamines显示文摘	Demetriou G Neonaki C Navakoudis E	2007	Biochimica et Biophysica Acta2007，1767，：	1
7	Clinical management of gastrointestinal stromal tumors: before and after sti- 571显示文摘	Dematteo RP Heinrich MC Demetri G	2002	Human Pathol2002，33，5：	1
8	Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors显示文摘	Demetri G D Von Mehren M Blanke C D	2002	N Engl J Med2002，347，7：	1
9	A damage-tolerant glass显示文摘	DEMETRIOU M D LAUNEY M E GARRETT G		0，，：	1
10	Molecular basis for sunitinib efficacy and future clinical development显示文摘	Faivre S Demetri G Sargent W	2007	Nat Rev Drug Discov2007，6，9：	1
11	SU11248,a multi-targeted tyrosine kinase inhibitor,can overcome imatinib (IM) resistance caused by diverse genomic mechanisms in patients (pts) with metastatic gastrointestinal stromal tumor (GIST)显示文摘	Demetri G D Desai J Fletcher J A	2004	Proc Am Soc Clin Oncol2004，，：	1
12	Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor显示文摘	Heinrich M C Corless C L Demetri G D	2003	J Clin Oncol2003，21，：	1
13	Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors显示文摘	Demetri G van Mehren M Blanke CD	2002	N Engl J Med2002，347，7：	1
14	Improved outcomes from adding sequential paclixaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node positive primary breast cancer 显示文摘	Henderson I C Berry D A Demetri G D	2003	J ClinOncol2003，21，6：	1
15	When and how do I use neoadjuvant chemotherapy for breast cancer显示文摘	Rapoport B L Demetriou G S Moodley S D	2014	Curr Treat Options Oncol2014，15，1：	1
16	Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with nodepositive primary breast cancer显示文摘	HENDERSON I C BERRY D A DEMETRI G D	2003	J Clin Oncol2003，21，6：	1
17	Long-term result from a randomized phase Ⅱtrial of standard versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT显示文摘	Blanke C D Demetri G D von Mehren M	2008	J Clin Oncol2008，26，4：	1
18	Granulocyte colony- stimulating factor and its receptor显示文摘	DEMETRI G D GRIFFIN J D	1991	Blood1991，78，：	1
19	Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients wieh node-positive primary breast cancer显示文摘	Henderson C Berry D A Demetri G D	2003	J Clin Oncol2003，21，6：	1
20	Molecular basis for sunitinib efficacy and future clinical development 显示文摘	Faivre S Demetri G Sargent W	2007	Nat Rev Drug Discov2007，6，9：	1

返回顶部每页显示：

共9页首页上一页第1页下一页末页 /9 跳转

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费

用户提示